bevacizumab + gemcitabine + nab-paclitaxel

The combination of bevacizumab, gemcitabine, and nab-paclitaxel is a chemotherapy regimen that has been studied in clinical trials for various advanced solid tumors, particularly pancreatic cancer. This combination brings together three distinct medications with complementary mechanisms of action. ## Drug Components **Bevacizumab (Avastin)** is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis and thereby reducing tumor blood supply[1][2]. **Gemcitabine (Gemzar)** is a nucleoside analog that works as a chemotherapy agent by disrupting DNA synthesis in rapidly dividing cells like cancer cells[3][5]. **Nab-paclitaxel (Abraxane)** is an albumin-bound formulation of paclitaxel that acts as a mitotic inhibitor, preventing cell division by stabilizing microtubules[3][4][5]. ## Clinical Development A phase I modified 3+3 dose escalation study evaluated this triple combination in patients with advanced solid tumors. The study enrolled 110 patients who had undergone a median of 3 prior lines of therapy, with a median age of 60 years. Notably, 50% of the patients had gemcitabine-refractory disease[1][6]. The study found that the combination was safe and well-tolerated, with only 3 dose-limiting toxicities observed during dose escalation and 3 in expansion cohorts. Based on this study, the recommended phase 2 dose was determined to be gemcitabine 1000 mg/m², nab-paclitaxel 125 mg/m², and bevacizumab 15 mg/kg[1]. ## Efficacy The triple combination showed promising activity in advanced malignancies, including gemcitabine-refractory tumors. In the phase I study, one patient with gemcitabine-refractory peritoneal papillary carcinoma achieved a complete response, 13 patients (13%) had partial responses, and 54 patients (52%) had stable disease for 12 weeks or longer[1]. ## Administration While specific administration details for the triple combination weren't fully detailed in the search results, the components are typically administered as follows: - Nab-paclitaxel is given as a drip over 30 minutes - Gemcitabine is given as a drip over 30 minutes - Bevacizumab is administered intravenously[3][6] The treatment cycle for gemcitabine and nab-paclitaxel typically follows a 28-day (4-week) schedule with treatment on days 1, 8, and 15, followed by a rest period[3][5]. ## Safety Profile The combination of bevacizumab with gemcitabine-based regimens has shown manageable toxicity profiles. Common adverse events associated with bevacizumab include bleeding, hypertension, and proteinuria[2][7]. The addition of bevacizumab to gemcitabine-based therapy has not been shown to significantly increase gastrointestinal perforation or arterial and venous thromboembolic events[2]. This triple combination represents an approach that targets multiple aspects of cancer biology: disrupting cell division (nab-paclitaxel), interfering with DNA synthesis (gemcitabine), and inhibiting angiogenesis (bevacizumab).

Other names

bevacizumab + paclitaxel + gemcitabinebevacizumab + nab-paclitaxel + gemcitabine